Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Growth Hormone Research Society Perspective on the Development of Long-Acting Growth Hormone Preparations

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Risk factors for hyperglycemia in pregnancy in the DALI study differ by period of pregnancy and OGTT time point

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. THERAPY OF ENDOCRINE DISEASE: Growth hormone replacement therapy in adults: 30 years of personal clinical experience

    Research output: Contribution to journalReviewResearchpeer-review

  3. Safety and convenience of once-weekly somapacitan in adult GH deficiency: a 26-week randomized, controlled trial

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. SGLT2 inhibitors: Clinical benefits by restoration of normal diurnal metabolism?

    Research output: Contribution to journalReviewResearchpeer-review

  5. Genetic influence on the associations between IGF-I and glucose metabolism in a cohort of elderly twins

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Increases in bioactive IGF do not parallel increases in total IGF-I during growth hormone treatment of children born SGA

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Measurement of peripheral arterial tonometry in patients with diabetic foot ulcers during courses of hyperbaric oxygen treatment

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. A Polygenic Risk Score Suggests Shared Genetic Architecture of Voice Break With Early Markers of Pubertal Onset in Boys

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Sex-specific estrogen levels and reference intervals from infancy to late adulthood determined by LC-MS/MS

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. The External Genitalia Score (EGS): A European multicenter validation study

    Research output: Contribution to journalJournal articleResearchpeer-review

  • Jens Sandahl Christiansen
  • Philippe Backeljauw
  • Martin Bidlingmaier
  • Beverly Biller
  • Margaret Boguszewski
  • Felipe F Casanueva
  • Philippe Chanson
  • Pierre Chatelain
  • Catherine S Choong
  • David R Clemmons
  • Laurie Cohen
  • Pinchas Cohen
  • Jan Frystyk
  • Adda Grimberg
  • Yukihiro Hasegawa
  • Morey Haymond
  • Ken Ho
  • Andrew R Hoffman
  • Jeff Mp Holly
  • Reiko Horikawa
  • Charlotte Hoybye
  • Jens Otto L Jorgensen
  • Gudmundur Johannsson
  • Anders Juul
  • Laurence Katznelson
  • John J Kopchick
  • K-O Lee
  • Kuk Wha Lee
  • Xiao-Ping Luo
  • Shlomo Melmed
  • Bs Miller
  • Madhusmita Misra
  • Vera Popović
  • Ron G Rosenfeld
  • Judith Ross
  • Richard J Ross
  • Paul Saenger
  • Christian J Strasburger
  • Michael O Thorner
  • Haim Werner
  • Kevin Cj Yuen
View graph of relations

OBJECTIVE: The Growth Hormone (GH) Research Society convened a workshop to address important issues regarding trial design, efficacy, and safety of long-acting GH preparations (LAGH).

PARTICIPANTS: A closed meeting of 55 international scientists with expertise in growth hormone, including pediatric and adult endocrinologists, basic scientists, regulatory scientists, and participants from the pharmaceutical industry.

EVIDENCE: Current literature was reviewed for gaps in knowledge. Expert opinion was utilized to suggest studies required to address potential safety and efficacy issues.

CONSENSUS PROCESS: Following plenary presentations summarizing the literature, breakout groups discussed questions framed by the planning committee. Attendees re-convened after each breakout session to share group reports. A writing team compiled the breakout session reports into a draft document that was discussed and revised in an open forum on the concluding day. This was edited further and then circulated to attendees from academic institutions for review after the meeting. Participants from pharmaceutical companies did not participate in the planning, writing, or in the discussions and text revision on the final day of the workshop. Scientists from industry and regulatory agencies reviewed the manuscript to identify any factual errors.

CONCLUSIONS: LAGH compounds may represent an advance over daily GH injections because of increased convenience and differing phamacodynamic properties, providing the potential for improved adherence and outcomes. Better methods to assess adherence must be developed and validated. Long-term surveillance registries that include assessment of efficacy, cost-benefit, disease burden, quality of life, and safety are essential for understanding the impact of sustained exposure to LAGH preparations.

Original languageEnglish
JournalEuropean journal of endocrinology / European Federation of Endocrine Societies
Volume174
Issue number6
Pages (from-to)C1-8
Number of pages9
ISSN0804-4643
DOIs
Publication statusPublished - 23 Mar 2016

ID: 46346499